What is known and objective
Treatment for diffuse large B‐cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug‐drug interactions, toxic effects and ART resistance must be considered.
Case description
A 40‐year‐old man with drug‐resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab‐uiyk was started to ensure he was on three active HIV medications.
What is new and conclusion
Ibalizumab‐uiyk has no known drug‐drug interactions and may be used as bridge therapy for patients with drug‐resistant HIV undergoing chemotherapy.